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Background: Sclerosing peritonitis (SP) is a rare but serious complication of peritoneal dialysis. Multiple
causes have been implicated in its pathogenesis. Different approaches to management include conservative
treatment, surgical intervention, and immunosuppressive therapy. We retrospectively reviewed the presentation
and treatment outcome of seven patients with SP.
Methods: Overall, 552 patients underwent continuous ambulatory peritoneal dialysis (CAPD) between 1994
and 2003. Patients were included if there were suggestive clinical features and either radiologic or surgical
evidence of SP. Seven patients developed SP, five men and two women, with a median age of 41 years (range,
32–64 years). The median duration of CAPD prior to development of SP was 72 months (range, 48–125
months). In six patients, SP occurred soon after an episode of CAPD-related peritonitis (range, 1–7 months).
Results: Patients presented with acute abdominal pain, ascites, small bowel intestinal obstruction, and failure
of Tenckhoff catheter reinsertion. Abdominal X-ray, ultrasonography, and computed tomography scans were
helpful in the diagnosis. Laparotomies were performed in six patients (typical cocoon appearance of peritoneum
in three). No patients underwent adhesiolysis or received immunosuppressive therapy. All patients were switched
to hemodialysis. Five patients required temporary total parenteral nutritional support. Four patients survived
but none returned to CAPD. The other three patients died of sepsis.
Conclusion: SP is a serious complication of peritoneal dialysis with a mortality rate of 43%. Severe peritonitis,
especially in patients on dialysis for longer than 4 years, is associated with development of SP. Prevention and
optimal treatment of CAPD-related peritonitis might be important in preventing SP. [Hong Kong J Nephrol
2004;6(2):79–86]
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INTRODUCTION
Sclerosing peritonitis (SP) is a rare but serious, and
sometimes fatal, complication of chronic ambulatory
peritoneal dialysis (CAPD). It is an inflammatory pro-
cess affecting the peritoneum diffusely, transforming
it into fibrous tissue [1]. It comprises a spectrum of
changes ranging from opacification, through tanned or
thickened peritoneum, to encapsulating SP in which
the small bowel is encapsulated, leading to bowel ob-
struction through obliteration of the peritoneal cavity
or through adhesions [1]. Multiple causes have been im-
plicated in the pathogenesis of SP. Management in-
cludes permanent cessation of CAPD, total parenteral
nutrition (TPN), immunosuppression, and surgery.
This retrospective study aimed to look at the pre-
sentation and treatment outcome in seven patients with
SP in our center.
METHODS
From 1994 to 2003, a total of 552 end-stage renal failure
patients received peritoneal dialysis therapy in our unit.
We recruited patients who developed SP. Presentation,
treatment, and outcome were determined in patients
who developed SP.
RESULTS
Seven patients developed SP. The median age was 41
years (range, 32–64 years). There were five men and
two women, and the prevalence of SP was 1.3%.
The causes of end-stage renal failure in this group
were chronic glomerulonephritis in three patients,
unknown in two, and diabetes mellitus in two. The
median duration of CAPD was 72 months (range, 48–
125 months). All patients had been on CAPD for more
than 4 years at the time of diagnosis of SP.
All seven patients had a history of CAPD-related
peritonitis (range, 1–8 episodes; median, 4; Table 1).
Methicillin-sensitive Staphylococcus aureus was the
causative organism in three patients, while other or-
ganisms included fungus, Xanthomonas, Klebsiella,
Escherichia coli, Bacteroides, Streptococcus viridans,
Enterococcus, and Rhodococcus (Table 1). In six pa-
tients, the onset of SP was soon after an episode of
CAPD-related peritonitis (range, 1–7 months), while
the remaining patient presented with acute abdominal
pain and small bowel intestinal obstruction after 3 years
of hemodialysis after peritoneal failure. The median
interval between the onset of peritonitis and removal
of the Tenckhoff catheter was 4 days (range, 1–10 days).
Ascites were present in three patients (Patients 3–5)
and clinical small bowel intestinal obstruction was pre-
sent in four patients. One patient was diagnosed with
SP when the surgeon failed to reinsert the Tenckhoff
catheter under general anesthetic (Patient 6).
Typical hyperechogenic strands were found on
abdominal ultrasonography in three patients (Patients
3–5) (Figure 1, Table 2). Three patients had evidence
of small bowel intestinal obstruction on abdominal X-
ray (Table 2, Figures 2 and 3). Loculated peritoneal
Table 1. Clinical data of patients with sclerosing peritonitis (SP) complicating continuous ambulatory peritoneal dialysis
Patient Age/sex No. Tenckhoff Onset (months
catheters on PD) No. Months between last peritonitis
episodes episode and SP onset Organisms involved*
1 37/F 2   72 2 36 Candida, Xanthomonas
2 64/M 2   77 8   7 Klebsiella, E. coli, Bacteroides,
  Streptococcus viridans,
  Enterococcus
3 41/M 2   60 5   3 CNS, Rhodococcus, non-glucose
fermenting Gram-negative bacilli
4 50/M 2   62 1   2 MSSA
5 48/M 2 125 4   2 MSSA
6 39/M 1 100 1   3 MSSA
7 32/F 2   48 4   1 Candida glabrata,
  Streptococcus viridans,
  Candida albicans
*Organism involved in last episode of peritonitis preceding onset of SP. PD = peritoneal dialysis; E. coli = Escherichia coli; CNS =
coagulase-negative Staphylococcus; MSSA = methicillin-sensitive Staphylococcus aureus.
Peritonitis preceding onset of SP
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collections and tethering of the small bowel were found
on computed tomography (CT) scan of the abdomen in
two patients.
Laparotomies were performed in six patients
because of suspected intraperitoneal abscess (Patient
7), suspected infective ascites (Patient 5), small bowel
intestinal obstruction (Patients 1, 2, and 4), and the need
to reinsert the Tenckhoff catheter for peritoneal dialysis
Figure 1. Abdominal ultrasonography showing hyperechogenic
strands (Patient 4).
Table 2. Presentation and outcome of patients with sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis
Patient
Presentation
Treatment Outcome
Symptoms Radiologic Laparotomy
1 Acute abdominal pain XR: dilated small bowel Matted small bowels involving TPN, HD Survived
   and small bowel the whole abdomen
   intestinal obstruction
2 Small bowel intestinal XR: dilated small bowel; CT: Typical cocoon TPN, HD Died of
   obstruction dilated small bowel loops (possibly sepsis
obstruction due to adhesion bands)
3 Ascites and small USG: hyperechogenic strands; — TPN, HD Died of
   bowel intestinal CT: loculated peritoneal collections sepsis
   obstruction and tethering of small bowels
4 Ascites and small XR and barium study: small bowel Typical cocoon TPN, HD Survived
   bowel intestinal intestinal obstruction; USG:
   obstruction hyperechogenic strands
5 Ascites USG: hyperechogenic strands Adhesions and clot-like material TPN, HD Survived
involving the whole abdomen
6 Failed reinsertion of — Severe adhesions of small bowels HD Survived
   TK catheter involving the whole abdomen
7 Peritonitis CT: inflammatory changes in Typical cocoon TPN, HD Died of
peritoneal cavity with loculated sepsis
collections
XR = X-ray; TPN = total parenteral nutrition; HD = hemodialysis; CT = computed tomography scan; USG = ultrasonography; TK =
Tenckhoff.
(Patient 6). The remaining patient was considered too
ill to have surgical intervention (Patient 3) and soon
died of sepsis. A typical cocoon appearance of the
peritoneum suggesting encapsulating SP was seen in
three patients (Figure 4), while other findings included
extensive matted small bowels and extensive adhesions
and clot-like materials involving the whole abdomen
(Table 2).
When SP was diagnosed, six patients were switched
to hemodialysis (Patients 2–7), while the remaining
patient was already on hemodialysis. Five patients
needed transient TPN, but no patients required long-
term TPN. Among the six patients who underwent
laparotomy, no active surgical interventions, such as ad-
hesiolysis, were performed because of the anticipated
difficulties (Table 2).
No immunosuppressive treatment was given.
However, at the time of diagnosis of SP, one patient
(Patient 1) who had undergone cadaveric renal trans-
plantation 3 years after the diagnosis of SP suffered
from two episodes of small bowel intestinal obstruction
post-transplantation that settled with conservative
management.
After a mean follow-up of 31.3 ± 46.1 months from
the diagnosis of SP, four patients had survived but none
had returned to CAPD. Among the four patients with
C.Y. Wong, et al
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intestinal obstruction, two recovered spontaneously
after 10 and 15 days, while the other two did not im-
prove and subsequently died of sepsis 4 weeks after
the onset of SP (Table 2). The mortality rate was 43%.
DISCUSSION
As SP is a spectrum of changes in the peritoneum
ranging from opacification, through tanned or thickened
peritoneum, to encapsulating SP where the small bowel
is encapsulated, leading to bowel obstruction through
obliteration of the peritoneal cavity or through adhe-
sions, we use the term SP to describe the whole dis-
ease entity [1]. The term “peritoneal sclerosis” simply
means the presence of sclerotic tissue in the peritone-
um. Qualitative and quantitative morphologic aspects
indicate that there are two nosologic entities: simple
sclerosis and SP. Simple sclerosis is a thin layer of
submesothelial sclerotic tissue often limited to certain
peritoneal areas, with monotonous histology. It is a
component of the slight anatomic alterations constant-
ly detectable in peritoneal dialysis patients. SP is
characterized by very thick sclerotic tissue involving
the whole peritoneal wall, often with inflammatory
infiltrates, microabscesses, giant cells of macrophagic
origin, calcification, and severe vascular alterations.
Intermediate stages between simple sclerosis and SP
have rarely been detected. Simple sclerosis and SP also
seem to be distinct with respect to frequency, etiology,
reproducibility in animal models, and clinical manifes-
tations [2].
Studies performed in CAPD populations have
estimated the prevalence of SP at 1–24% [3]. An
Australian study reported a mean annual incidence of
2.7 per 1,000 peritoneal dialysis treatment periods [1].
The annual incidence from more recent studies is higher
than that from older studies, probably because of the
longer duration of peritoneal dialysis therapy received
by patients now compared with the past. The length of
time on peritoneal dialysis is believed to have an im-
portant impact on the development of SP [1]. This fac-
Figure 2. Abdominal X-ray showing small bowel intestinal obstruc-
tion (Patient 4).
Figure 3. Follow-through study showing hold-up of contrast at duo-
denal cap, suggestive of total small bowel obstruction (Patient 4).
Figure 4. Laparotomy showing matted bowels and intra-abdominal
loculation (Patient 4).
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tor seems particularly important in our renal patients
because they are more likely to remain on peritoneal
dialysis for longer due to the long cadaveric renal
transplant waiting list locally [4]. However, the esti-
mation of the appropriate frequency of SP is difficult
because there is no agreement on the definitions or
diagnostic criteria for SP.
Predominance of both sexes has been reported [5–
10], with age of onset in the fourth to sixth decade of
life [5,6,8–14]. The median age was 41 years in our
study, which is similar to reported series. Chronic glo-
merulonephritis is the most common cause of end-stage
renal disease in patients diagnosed with SP (36–100%)
[6,9,10,12].
The reaction of peritoneal mesothelium and stroma
to the stress of continuous dialysis results in a spectrum
of alterations ranging from opacification through a
tanned peritoneum syndrome to encapsulating SP [15].
Any agents that cause irritation of the mesothelial layer
and induce serositis, or single severe or multiple epi-
sodes of peritonitis resulting in mesothelial loss, would
predispose to fibroneogenesis [15]. It is evident that
fibrin deposition and fibrinolysis, hyalinization of the
superficial stromal collagen (possibly tanned through
non-enzymatic glycosylation by dialysate glucose), and
the proliferative potential of mesothelial stem cells play
important and possibly interdependent roles in the ex-
cessive fibroneogenesis in certain patients on CAPD
[15]. However, the complete picture of the pathogenesis
of SP is still not entirely known.
The etiology is usually uncertain and is likely to be
multifactorial [1]. Different factors may act alone or
simultaneously to trigger and perpetuate the process
that leads to peritoneal fibrosis and SP [1]. Early studies
found that formalin antiseptic, chlorhexidine in alcohol
sterilizing sprays, multiple abdominal surgeries [2],
acetate and lactate buffered dialysates, endotoxin from
in-line bacterial filters, and severe peritonitis with
chlorhexidine antiseptic may be possible predisposing
factors [16]. Plasticizers and particulate matter in the
dialysate, as well as the hypertonicity and acidity of
the dialysate, have also been implicated. Dextrose itself
is toxic to the peritoneum due to passive glycosylation
of the submesothelial tissue when the mesothelium is
breached due to injury, for example, in the setting of
peritonitis. Heat sterilization of the dialysate results in
glucose degradation products, which are major cyto-
toxicity factors in peritoneal dialysis solutions [15].
SP usually occurs in patients who have been on
peritoneal dialysis therapy for more than 4–5 years [6,
10,17], as seen in all of our patients. In the Australian
study, the prevalences of SP were 1.9%, 6.4%, 10.8%,
and 19.4% in patients on dialysis for more than 2, 5, 6,
and 8 years, respectively, emphasizing the importance
of duration of peritoneal dialysis in the development
of SP [1]. This suggests that dialysis solutions may be
the pathogenetic factor for SP [18]. Commercial peri-
toneal dialysis fluids may induce a state of chronic
sterile inflammation in the peritoneal cavity, thereby
activating macrophages that produce cytokines such
as interleukin-2 and tumor necrosis factors alpha and
beta [3,19,20]. These cytokines increase synthesis of
collagen by mesothelial cells and fibroblasts [3,19,20].
Previous in vitro studies have shown upregulation of
type III collagen expression by exposure of mesothelial
cells to peritoneum effluent from patients with perito-
nitis [19,20].
The presence of peritoneal dialysis catheters could
also promote an inflammatory foreign body response
[21–24], predisposing the peritoneum to sclerosis.
Similar peritoneal responses have been described in
cirrhotic patients with indwelling Le Veen shunts or in
patients with ventriculoperitoneal shunts [7,12,13,23–
28]. Six of our cases had had more than one peritoneal
dialysis catheter inserted because of CAPD-related
peritonitis. In the past, in-line bacterial filters have been
used and attached to dialysate tubing [2]. Bacteria
trapped in the filters secrete pyrogens, which cross
the filters and enter the peritoneal cavity where they
stimulate macrophages to secrete interleukin-1, result-
ing in peritoneal fibrogenesis [29]. However, Oules
et al found no significant difference in the incidence
of SP between those who were or were not exposed
to bacterial filters [6]. None of our patients had been
exposed to in-line bacterial filters.
Peritonitis appears critical in the development of SP.
There is loss of peritoneal mesothelium and exposure
of subserosal stroma to high concentrations of glucose
in the dialysate, resulting in protein glycosylation [2].
Secondary thickening and duplication of basement
membranes and changes in the collagen and matrix
occur [2]. The mesothelium secretes prostaglandins,
lubricant surfactants, and tissue plasminogens. The
loss of mesothelium and its fibrinolytic activity at the
time of increased exudation of fibrin in the setting of
peritonitis produces an imbalance between fibrinoly-
sis and fibrinogenesis [24]. A fibrin mantle forms and
progressively organizes to result in a new sheet of
fibrous tissue. The uncontrolled proliferation of mes-
enchymal stem cells in the setting of mesothelium dam-
age may contribute to the fibrosis process by the pro-
duction of excess fibroconnective tissue [15].
Peritoneal sclerosis progresses in stages. In the
initial stage, peritoneal membrane opacification is
due to widespread cellular loss. The peritoneum then
becomes dry, thickened, wrinkled, and light brown in
color (tanned peritoneum) [7,15]. In the more advanced
stage, the diffuse sclerosing process extends trans-
murally with incorporation of the inner circular muscle
layer and myenteric plexus of the small bowel. Finally,
a fibrous neomembrane encapsulates the small bowel
in a cocoon [15]. The stomach, spleen, gallbladder, liver,
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and pelvic organs may also be involved [15].
Theoretically, as peritoneal dialysis removes fibrin
and inflammatory mediators during peritonitis, cessa-
tion of dialysis may promote fibrin accretion, and this
has been implicated in the development and progression
of SP [15]. Particular organisms that may be more likely
to cause SP include S. aureus, Pseudomonas, and fungi
[5,30]. In our patients, methicillin-sensitive S. aureus
was the most common cause of CAPD peritonitis
immediately prior to the onset of SP. Six of the seven
patients (86%) had had CAPD peritonitis that required
removal of peritoneal dialysis catheters because of lack
of improvement with intraperitoneal antibiotics.
Beta-blockers have also been implicated in the de-
velopment of fibrosis in all serous cavities, including
peritoneal fibrosis [9,23,24]. Practolol, which has been
withdrawn from the market, is the most commonly
implicated beta-blocker in the pathogenesis of SP [20].
Metoprolol, propranolol, and atenolol have also been
linked to SP [12]. Beta-blockers inhibit the synthesis
and release of surfactants, which act as lubricants in
the peritoneum, resulting in mesothelial abrasion and
loss, together with fibrin exudation [18]. Two of our
SP patients had received a beta-blocker. Charney and
Gouge reported that chemical peritonitis could be
caused by intraperitoneal administration of vanco-
mycin at high doses (1–2 g) [31]. Three of our patients
had a history of intraperitoneal vancomycin adminis-
tration 3–41 months prior to the development of
SP. Chlorhexidine in alcohol and povidone iodine
antiseptics, which were previously used for sterilizing
tubing spikes before connection, are implicated in
causing SP [3,5,7,11,13,22]. None of our patients had
such exposure.
Clinical features of SP can be variable and include
gastrointestinal manifestations such as abdominal
pain, nausea and vomiting, ascites, and blood-stained
dialysate, combined with weight loss and a decline in
peritoneal ultrafiltration. Initially, the decline in ultra-
filtration is type I, but, at a later stage, may convert
to type II [7,10–12,15]. The onset is often insidious,
but subacute small bowel obstruction heralds the on-
set of severe disease that may progress to multiple epi-
sodes of bowel obstruction. The incidence of bowel
obstruction is 50% higher among adolescent patients
than among adults [3,7,11,24,28]. SP may present only
after transfer to hemodialysis, as in one of our patients
who had been switched to hemodialysis because of
ultrafiltration failure secondary to severe fungal peri-
tonitis 3 years prior to the onset of SP. Severe peritonitis
may immediately precede the diagnosis, as in most of
our cases, but the condition often presents some months
after peritoneal dialysis has been stopped, as a result
of peritonitis or other reasons. The time between the
first clinical symptom and diagnosis of SP varies from
a few weeks to 15 months [12,20].
Radiologic findings are useful to support the clinical
diagnosis of SP. Krestin and Kacl concluded that
detection of characteristic radiologic signs in patients
on CAPD presenting with symptoms of intestinal ob-
struction may suggest the diagnosis of SP [32].
Abdominal X-ray findings suggestive of SP include
calcifications in the peritoneum and intestinal wall.
Dilated small bowel loops with air-filled levels sug-
gestive of small bowel intestinal obstruction may be
present. On barium meal and small bowel follow-
through examinations, the presence of delayed bowel
transit and separated rigid, dilated, and fixed small
bowel loops with air-fluid levels are also suggestive of
SP. Other features include varying degrees of obstruc-
tion accompanied by hypermobility of some loops of
small bowel [18]. The typical abnormalities seen on
ultrasound examination include increased small bowel
peristalsis, tethering of the bowel to the posterior ab-
dominal wall, intraperitoneal echogenic strands and,
in the late stage of the disease, membrane formation.
Optimal visualization of these features in the early
stages of the disease is obtained by examining patients
with dialysis fluid present in the abdomen [33].
CT scan is the most sensitive early test to look for
calcifications. Other features observed on CT scan in-
clude peritoneal thickening, loculated fluid collec-
tions, and tethering of the small bowel.
The differential diagnoses of SP include tubercu-
losis, peritoneal mesothelioma, and pseudomyxoma
peritonei [34]. A definitive diagnosis can usually be
made at laparoscopy or laparotomy and subsequent
histologic examination of peritoneal biopsies. On lap-
arotomy or postmortem examination, SP is charac-
terized by a thickened fibroconnective sheath that
encapsulates some or all of the small intestine in a
cocoon-like sac during dissection, and fibrous bands
may be found between loops of bowel. The cocoon
compresses and obstructs the bowel, preventing it
from dilatation. Parietal involvement may be present;
occasionally, the stomach, spleen, liver, gallbladder,
duodenum, colon, and pelvic organs are involved [15,
19,21,28]. Characteristic peritoneal histologic changes
comprise fibroconnective tissue proliferation, absence
of mesothelium from the surface of the new fibrous
tissue with opacification of the peritoneum, chronic
inflammatory infiltrate of variable density, and dilated
lymphatics without evidence of foreign body granu-
lomas, giant cells, or birefringent material [9,11,15,20,
28].
The choice between surgical or conservative ther-
apy remains controversial. TPN is well established as
an integral element of both approaches [9,17,22]. De-
spite isolated reports of successful outcomes after sur-
gical intervention, surgery has usually been hazardous
because of the difficulties in finding a clear plane of
cleavage between the membrane and the bowel during
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attempts to free the small bowel. Making multiple re-
leasing incisions in the thickened membrane to free the
underlying bowel is an alternative approach. Surgery
has been associated with a high mortality rate because
of the high rates of postoperative complications that
include persistent or recurrent intestinal obstruction,
formation of fistulas and abscesses, malnutrition, and
sepsis [9,20,28,29]. Bhandari et al suggest that pre-
operative immunosuppression can facilitate dissection
during subsequent surgery and can improve patient
outcome [35].
SP may also improve without surgical intervention
[9,15,21,27]. A conservative approach involves cessa-
tion of peritoneal dialysis, removal of the Tenckhoff
catheter with switching to hemodialysis, sustained rest
of the bowels, and TPN [5,7,9,10,22,35]. As peritoneal
dialysis may act to continuously remove fibrin, and thus
prevent further deposition and organization, cessa-
tion of peritoneal dialysis might actually accelerate
the progress of SP [11,24,27]. However, the diagnosis
of SP is usually made at a stage when the peritoneum
can no longer work as a means of dialysis, and a switch
to hemodialysis seems to be the only option in many
patients [10,32,35].
Although not universally reported, immunosuppres-
sive therapy (steroid alone or combined with cytotoxics)
is beneficial in the treatment of SP. Immunosuppressive
therapy (prednisone 30–50 mg daily, azathioprine 100–
125 mg daily) alone or combined with renal transplant
has resulted in prolonged remission in patients with
SP [9,10,13,22,35,36]. Junor and McMillan reported
that five such patients treated with immunosuppression
(one without transplantation) survived, whereas the 12
patients not given immunosuppression all died [36].
They postulated that SP improved with transplantation
because of the anti-inflammatory effects of the immuno-
suppressive therapy and the reversal of the uremic state
after successful transplantation. However, the gas-
trointestinal dysfunction associated with uremia is
usually modest, and thus reversal of uremia is a rather
unlikely mechanism to solely explain the benefits of
renal transplantation in patients with SP. On the other
hand, it has been suggested that the anti-inflammatory
action of the immunosuppressive therapy used in re-
nal transplantation is pivotal in the mechanism of recov-
ery of gut function [37]. None of our patients with SP
received immunosuppressive therapy, either because of
spontaneous improvement or the presence of clinical
sepsis. It is often difficult to totally exclude the possibi-
lity of ongoing sepsis in a patient with abdominal signs
soon after an episode of severe peritonitis.
In a case report by Fagugli et al, colchicine was
added to immunosuppressive therapy consisting of
prednisone and azathioprine in a patient with severe
SP who subsequently survived and returned to a normal
diet [38]. Colchicine is effective in decreasing hepatic
fibrosis [39] and idiopathic pulmonary fibrosis [40,41].
The mechanism appears to be linked to the inhibition
of fibroblast proliferation and total collagen secretion
from this cellular line. On the immunosuppressive
aspect, colchicine acts on T lymphocytes to down-
regulate L-selectin, leukocyte function-associated
antigen-1, and interleukin-2 receptor expression [42].
Pirfenidone, an antifibrotic agent, markedly inhibits or
prevents fibrotic changes in experimental SP induced
in rats by chlorhexidine [43]. However, data from hu-
man studies are not available.
As SP is associated with a high mortality rate, pre-
vention would be more effective than treatment [32].
We should focus on the prevention of CAPD peritonitis
[8]. In severe peritonitis, we should always consider
early removal of the catheter to avoid severe peritoneal
damage [15]. The use of glucose polymer-based peri-
toneal dialysis fluid may be beneficial in the preven-
tion of SP [2].
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